Literature DB >> 15098011

Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node.

Alistair J Cochran1, Duan-Ren Wen, Rong-Rong Huang, Hei-Jing Wang, Robert Elashoff, Donald L Morton.   

Abstract

Lymphatic mapping and sentinel node biopsy are well-established techniques for staging and managing patients with melanoma, breast cancer and other malignancies that spread initially to the regional lymph nodes. Identification of tumor in the sentinel node is the most precise staging technique currently available. The sentinel node is the site of metastatic melanoma in approximately 20% of melanoma patients and if tumor is present in the sentinel node it is customary to perform a complete dissection of the lymph nodes of the affected nodal basin. This may be overtreatment for some patients as tumor is identified in the nonsentinel nodes of only one-third of sentinel node-positive melanoma patients treated by completion lymphadenectomy. If it were possible accurately to identify the minority of patients with tumor in the nonsentinel nodes, the patients most likely to benefit from lymphadenectomy, the remaining patients could be spared a potentially morbid operation that is unlikely to confer clinical advantage. In 90 patients with a melanoma-positive sentinel node, who subsequently had a completion lymphadenectomy, we evaluated and compared the capacity of characteristics of the primary melanoma and of the sentinel node to predict individuals likely to have tumor in nonsentinel nodes. We assessed the Breslow thickness of the primary, the amount of tumor in the sentinel node (relative tumor area) and, as an index of immune modulation of the sentinel node, the density of dendritic leukocytes in the nodal paracortex. The relative area of tumor in the sentinel node and Breslow thickness of the primary melanoma most accurately predicted the presence of tumor in the nonsentinel nodes (P=0.0001 in both cases-Wilcoxon rank sums). The presence of melanoma in the nonsentinel nodes was also predicted by the density of dendritic leukocytes in the paracortex (P=0.008-Wilcoxon rank sums). These three observations assessed alone and in combination predict the presence of tumor in the nonsentinel nodes with high accuracy. The same characteristics also significantly correlated with tumor recurrence (tumor burden, P=0.0001, Breslow, P=0.0001 and dendritic cell density, P=0.0007) and death from melanoma (tumor burden, P=0.0001, Breslow, P=0.0001 and dendritic cell density, P=0.0026). Copyright 2004 USCAP, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098011     DOI: 10.1038/modpathol.3800117

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  25 in total

Review 1.  Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Authors:  Donald L Morton
Journal:  Clin Exp Metastasis       Date:  2012-06-24       Impact factor: 5.150

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

3.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.

Authors:  Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 9.236

4.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

5.  A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.

Authors:  Ahmad A Tarhini; Theofanis Floros; Hui-Min Lin; Yan Lin; Zahra Rahman; Madeeha Ashraf; Priyanka Vallabhaneni; Cindy Sander; Uma N M Rao; Monica Panelli; William A LaFramboise; John M Kirkwood
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

6.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 7.  Treatment strategy for cutaneous malignant melanoma.

Authors:  Arata Tsutsumida; Hiroshi Furukawa; Yuhei Yamamoto; Tsuneki Sugihara
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

Review 8.  Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.

Authors:  Alexander C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2010-06-22       Impact factor: 66.675

9.  Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.

Authors:  Rajmohan Murali; Alistair J Cochran; Martin G Cook; Joseph D Hillman; Rooshdiya Z Karim; Marc Moncrieff; Hans Starz; John F Thompson; Richard A Scolyer
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

10.  Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma.

Authors:  Jeffrey E Gershenwald; Robert H I Andtbacka; Victor G Prieto; Marcella M Johnson; A Hafeez Diwan; Jeffrey E Lee; Paul F Mansfield; Janice N Cormier; Christopher W Schacherer; Merrick I Ross
Journal:  J Clin Oncol       Date:  2008-07-07       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.